Old Web
English
Sign In
Acemap
>
authorDetail
>
Yun-Kai Zhang
Yun-Kai Zhang
Vanderbilt University Medical Center
Cancer research
Mutant
Biology
EGFR Activating Mutation
EGFR inhibitors
3
Papers
49
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting.
2021
Nature Communications
Zhenfang Du
Benjamin P. Brown
Soyeon Kim
Donna C Ferguson
Dean Pavlick
Gowtham Jayakumaran
Ryma Benayed
Jean-Nicolas Gallant
Yun-Kai Zhang
Yingjun Yan
Monica Red-Brewer
Siraj M. Ali
Alexa B. Schrock
Ahmet Zehir
Marc Ladanyi
Adam W. Smith
Jens Meiler
Christine M. Lovly
Show All
Source
Cite
Save
Citations (7)
Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer
2021
Journal of Thoracic Oncology
Portia L. Thomas
Sarah M. Groves
Yun-Kai Zhang
Jia Li
Paula I. Gonzalez-Ericsson
Shamilene Sivagnanam
Courtney B. Betts
Hua-Chang Chen
Qi Liu
Cindy Lowe
Heidi Chen
Kelli L. Boyd
Prasad R. Kopparapu
Yingjun Yan
Lisa M. Coussens
Vito Quaranta
Darren R. Tyson
Wade T. Iams
Christine M. Lovly
Show All
Source
Cite
Save
Citations (1)
On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation
2019
Clinical Cancer Research
Benjamin P. Brown
Yun-Kai Zhang
David Westover
Yingjun Yan
Huan Qiao
Vincent Huang
Zhenfang Du
Jarrod A. Smith
Jeffrey S. Ross
Vincent A. Miller
Siraj M. Ali
Lyudmila Bazhenova
Alexa B. Schrock
Jens Meiler
Christine M. Lovly
Show All
Source
Cite
Save
Citations (41)
1